Head-to-head evidence
liraglutide vs TG103
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: GLP-1 receptor · full Obesity pipeline
liraglutide · Saxenda / Victoza
Marketed by Novo Nordisk
NCT00781937 · Phase 3 · completed
The trial randomly assigned 212 participants to liraglutide and 210 to placebo in a double-blind, placebo-controlled design, with objective body-weight outcomes assessed at week 56. All three prespecified primary comparisons favored liraglutide and were statistically significant (each p<0.0001), supporting a strong evidence grade.
Next expected readout: December 2026 · NCT07225816 (registry estimate)
TG103
Developed by CSPC Pharmaceutical Group
NCT05997576 · Phase 3 · completed
The study was randomized, double-blind, and placebo-controlled, with 675 participants and clinical primary outcomes measuring weight loss. However, no trial results are posted, so whether the primary endpoints were met cannot be determined.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: liraglutide's landscape · TG103's landscape